This case report presents the clinical findings and management of a 62-year-old patient with a history of hemicolectomy and hepatic metastasis. The patient was diagnosed with microsatellite instability-high colon cancer and was treated with pembrolizumab. However, the patient developed hypothyroidism 2 months after the treatment as a side effect. This report highlights the importance of monitoring thyroid function in patients receiving pembrolizumab and discusses the management strategies for pembrolizumab-induced hypothyroidism.
No takes yet. Share an insight, caveat, or question.
- et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: